Search clinical trials for: TECENTRIQ

Total 402 results

University of Kansas Medical Center

Not yet recruiting

Dose-escalation Study of Ultra-high Dose Ablative Radiosurgery With Immunotherapy for Bulky Metastatic Cancer Patients

Solid Tumor

United States
NovoCure GmbH

Recruiting

EF-39 PANOVA-4: Study of Tumor Treating Fields Concomitant With Atezolizumab, Gemcitabine and Nab-Paclitaxel as First-LineTreatment for Metastatic Pancreatic Ductal Adenocarcinoma

Metastatic Pancreatic Ductal Adenocarcinoma

Spain
The Netherlands Cancer Institute
Hoffmann-La Roche

Not yet recruiting

NOvel Immunotherapy Strategies for Advanced Triple Negative Breast Cancer (TNBC) Patients: TONIC-3 Trial (TONIC-3)

Metastatic Breast Cancer
Hoffmann-La Roche

Recruiting

A Study of Adjuvant Atezolizumab or Atezolizumab Plus Tiragolumab in Solid Tumors With Resectable Disease With Intermediate-High Risk of Recurrence and High Tumor Mutational Burden (TMB-H) or Microsatellite Instability (MSI-H) (IMperator)

Solid Tumors

Spain
National Cancer Institute (NCI)

Not yet recruiting

Testing the Combination of Anti-cancer Drugs Tiragolumab and Atezolizumab to Improve Outcomes for Patients With Recurrent Glioblastoma

Recurrent Glioblastoma, IDH-Wildtype
Inimmune Corporation
Avance Clinical Pty Ltd.

Not yet recruiting

Trial of INI-4001 in Patients With Advanced Solid Tumours

Advanced Solid Tumor

Australia
National Cancer Institute (NCI)

Not yet recruiting

Testing the Combination of an Anti-cancer Drug, Iadademstat, With Other Anti-cancer Drugs (Atezolizumab or Durvalumab) at Improving Outcomes for Small Cell Lung Cancer

Stage IV Lung Cancer AJCC v8 | Extensive Stage Lung Small Cell Carcinoma
Hoffmann-La Roche

Recruiting

A Study of Tiragolumab Plus Atezolizumab Compared With Placebo Plus Atezolizumab in Participants With Completely Resected Non-small Cell Lung Cancer Who Have Received Adjuvant Platinum-based Chemotherapy (SKYSCRAPER-15)

Non-small Cell Lung Cancer (NSCLC)

Korea, Republic of, United States, China, Japan, Australia, Taiwan, Brazil, Argentina, Hong Kong
Emory University
National Cancer Institute (NCI); Genentech, Inc.

Recruiting

Pre-operative Atezolizumab in Patients With Resectable, Human Papillomavirus Related Oropharyngeal Carcinoma

Oropharynx Cancer, Stage I

United States
Nykode Therapeutics ASA
Roche Pharma AG; GOG Foundation

Recruiting

Efficacy and Safety of VB10.16 Alone or in Combination With Atezolizumab in Patients With Advanced Cervical Cancer.

Cervical Cancer | HPV-Related Malignancy | HPV-Related Cervical Carcinoma

United States
Genentech, Inc.

Recruiting

A Study Evaluating Atezolizumab, With or Without Bevacizumab, in Patients With Unresectable Hepatocellular Carcinoma and Child-Pugh B7 and B8 Cirrhosis (Kirros)

Hepatocellular Carcinoma

United States, Puerto Rico
Institut Curie
Roche Pharma AG; Replimune Inc.

Not yet recruiting

"neoBREASTIM": Atezolizumab Plus RP1 Oncolytic Immunotherapy in the NeoAdjuvant Setting of Triple-Negative Breast Cancer (neoBREASTIM)

Triple Negative Breast Neoplasms

France
National Cancer Institute (NCI)

Not yet recruiting

A Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing

Metastatic Melanoma | Locally Advanced Melanoma | Metastatic Alveolar Soft Part Sarcoma | Metastatic Non Small Cell Lung Cancer | Metastatic Hepatocellular Carcinoma | Locally Advanced Hepatocellular Carcinoma | Metastatic Small Cell Lung Cancer | Locally Advanced Non Small Cell Lung Cancer | Locally... and other conditions

United States
Christine Ryan
Genentech, Inc.

Recruiting

A Ph 2 Study of Glofitamab Alone or in Combination With Polatuzumab Vedotin or Atezolizumab in Richter's Transformation

Chronic Lymphocytic Leukemia | Richter's Transformation

United States
Genentech, Inc.

Recruiting

A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7566802 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors

Locally Advanced Solid Tumors | Metastatic Solid Tumors | Recurrent Solid Tumors

Australia, United States, Canada
The Netherlands Cancer Institute

Not yet recruiting

LB-100 (PP2A Inhibitor) and Atezolizumab (PD-L1 Inhibitor) in Metastatic Colorectal Cancer Patients (CoLBAt)

Metastatic Microsatellite-stable Colorectal Cancer
Emory University
National Cancer Institute (NCI)

Not yet recruiting

Cabozantinib in Combination With Atezolizumab for the Treatment of Patients With Locally Advanced, Metastatic, or Unresectable Adrenal Cortical Cancer

Adrenal Cortical Carcinoma | Stage III Adrenal Cortex Carcinoma | Stage IV Adrenal Cortex Carcinoma AJCC v8 | Unresectable Adrenal Cortex Carcinoma | Locally Advanced Adrenal Cortex Carcinoma

United States
Omico
Hoffmann-La Roche; The George Institute for Global Health, Australia

Recruiting

Tiragolumab and Atezolizumab in Advanced Pan-cancer Patients (MoST-TAP)

Solid Tumor, Adult

Australia
Genentech, Inc.
BioNTech SE

Recruiting

A Study of the Efficacy and Safety of Adjuvant Autogene Cevumeran Plus Atezolizumab and mFOLFIRINOX Versus mFOLFIRINOX Alone in Participants With Resected Pancreatic Ductal Adenocarcinoma (IMCODE003)

Adenocarcinoma, Pancreatic Ductal

United States, Canada, United Kingdom
Hoffmann-La Roche

Recruiting

A Study Evaluating The Efficacy and Safety of Neoadjuvant Immunotherapy Combinations in Patients With Surgically Resectable Hepatocellular Carcinoma

Carcinoma, Hepatocellular

Korea, Republic of, Taiwan, United States, France, Spain, New Zealand, United Kingdom
Hoffmann-La Roche
Chugai Pharmaceutical

Recruiting

A Study Evaluating Atezolizumab and Bevacizumab, With or Without Tiragolumab, in Participants With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma (IMbrave152) (SKYSCRAPER-14)

Carcinoma, Hepatocellular

United States, Canada, Korea, Republic of, Taiwan, Brazil, Belgium, China, Puerto Rico, Japan, New Zealand, Mexico, Spain, Germany, Poland, Thailand, Singapore, Hong Kong, France, Turkey, Italy, United Kingdom, South Africa, Côte D'Ivoire
Baylor College of Medicine
Genentech, Inc.

Not yet recruiting

Neoadjuvant Chemoimmunotherapy for Resectable Non-Metastatic Proficient Mismatch Repair (PMMR) Colon Cancer

Stage I Colon Cancer | Stage II Colon Cancer | Stage III Colon Cancer

United States
Genentech, Inc.
Chugai Pharmaceutical Co.

Recruiting

A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7496353 in Combination With a Checkpoint Inhibitor With or Without Standard-of-Care Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors

Gastric Cancer | Metastatic Solid Tumor | Non-small Cell Lung Cancer | Pancreatic Ductal Adenocarcinoma

Korea, Republic of, Spain, Japan, New Zealand, Australia, United States, Italy, Brazil
Jun Zhang, MD, PhD
Genentech, Inc.; Exelixis

Not yet recruiting

A Study of Combining Cabozantinib and Atezolizumab for Advanced/Metastatic NSCLC (Cabatezo-1) (Cabatezo-1)

Lung Cancer | NSCLC Stage IV | Advanced NSCLC | Metastatic NSCLC - Non-Small Cell Lung Cancer

United States
Peking University People's Hospital
Peking University First Hospital; Beijing Friendship Hospital; Chinese PLA General... and other collaborators

Recruiting

Low-dose Baricitinib Plus Danazol for Steroid-resistant/Relapse Immune Thrombocytopenia

Immune Thrombocytopenia

China
National Cancer Institute (NCI)

Recruiting

Testing Immunotherapy (Atezolizumab) With or Without Chemotherapy in Locoregional MSI-H/dMMR Gastric and Gastroesophageal Junction (GEJ) Cancer

Gastric Adenocarcinoma | Clinical Stage III Gastric Cancer AJCC v8 | Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8 | Gastroesophageal Junction Adenocarcinoma | Clinical Stage I Gastric Cancer AJCC v8 | Clinical Stage II Gastric Cancer AJCC v8 | Clinical Stage IVA Gastric... and other conditions

United States
Institut für Klinische Krebsforschung IKF GmbH...
Roche Pharma AG; Thoraxklinik-Heidelberg gGmbH

Recruiting

NeoTRACK - Dissection of IO Efficacy in NSCLC by Longitudinal tracKing

Non-small Cell Lung Cancer

Germany
Alliance Foundation Trials, LLC.
Genentech, Inc.

Recruiting

Atezolizumab Immunotherapy With or Without Tiragolumab for Patients With Unresectable Stage III NSCLC

NSCLC

United States
Intergroupe Francophone de Cancerologie Thoracique

Recruiting

Combination of Paclitaxel-bevacizumab ± Atezolizumab in Patients With Advanced NSCLC Progressing After Immunotherapy & Chemotherapy (ADAPTABLE)

Non Small Cell Lung Cancer

France
Yale University
Genentech, Inc.

Recruiting

Atezolizumab and Bevacizumab in Combination With TACE for Patients With BCLC B HCC

Hepatocellular Carcinoma | BCLC Stage B Hepatocellular Carcinoma

United States
Cancer Research UK
Royal Marsden NHS Foundation Trust; Hoffmann-La Roche; University of Manchester; University of Birmingham

Recruiting

DETERMINE Trial Treatment Arm 02: Atezolizumab in Adult, Teenage/Young Adults and Paediatric Patients With Cancers With High Tumour Mutational Burden (TMB) or Microsatellite Instability-high (MSI-high) or Proven Constitutional Mismatch Repair Deficiency (CMMRD) Disposition (DETERMINE)

Melanoma | Neoplasms by Histologic Type | Lymphoproliferative Disorders | Neoplasms by Site | Cancer | Colorectal Neoplasms | Endometrial Neoplasms | Malignant Neoplasm | Malignancy

United Kingdom
Liza Villaruz, MD
Genentech, Inc.

Recruiting

Carboplatin, Pemetrexed, and Atezolizumab in Patients With Non-squamous Non-small Cell Lung Cancer (NSCLC) and Untreated Brain Metastases

Non-small Cell Lung Cancer

United States
Cancer Research UK
Royal Marsden NHS Foundation Trust; Hoffmann-La Roche; University of Manchester; University of Birmingham

Recruiting

DETERMINE (Determining Extended Therapeutic Indications for Existing Drugs in Rare Molecularly Defined Indications Using a National Evaluation Platform Trial) - Master Screening Protocol (DETERMINE)

Solid Tumor | Haematological Malignancy

United Kingdom
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Improving Response to Immunotherapy in Patients With Advanced Hepatocellular Carcinoma and Chronic Hepatitis C Virus Infection With Direct-Acting Antiviral Therapy

Liver Cancer

United States
National Cancer Institute (NCI)

Recruiting

Testing the Combination of Anti-cancer Drugs Atezolizumab and Tiragolumab in People With Advanced Stage Rare Cancers, RARE3 Trial

Advanced Rare Malignant Solid Neoplasm | Rare Malignant Solid Neoplasm | Refractory Rare Malignant Solid Neoplasm

United States
Tongji Hospital
The Second Affiliated Hospital of Fujian Medical University; Geneplus-Beijing... and other collaborators

Recruiting

Combined TACE, TKI/Anti-VEGF and ICIs as Conversion Therapy for Advanced Hepatocellular Carcinoma (CCGLC-008)

Hepatocellular Carcinoma Non-resectable

China
Wan-Guang Zhang
The Second Affiliated Hospital of Fujian Medical University; Geneplus-Beijing... and other collaborators

Recruiting

Combined HAIC, TKI/Anti-VEGF and ICIs as Conversion Therapy for Unresectable Hepatocellular Carcinoma (CCGLC-001)

Hepatocellular Carcinoma Non-resectable

China
Genprex, Inc.

Recruiting

Quaratusugene Ozeplasmid (Reqorsa) and Atezolizumab Maintenance Therapy in ES-SCLC Patients (Acclaim-3)

Small Cell Lung Cancer Extensive Stage

United States
Nikolaj Frost MD
Roche Pharma AG; Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus...

Recruiting

Pemetrexed-free vs. Pemetrexed-based Immunochemotherapy in Metastatic TTF-1 Negative Lung Adenocarcinoma (ANTELOPE)

Non-Small Cell Lung Cancer Metastatic

Germany
M.D. Anderson Cancer Center
Genentech, Inc.

Recruiting

Phase 2 Trial of Neoadjuvant and Adjuvant Tiragolumab Plus Atezolizumab in Patients With Newly Diagnosed PD-L1 CPS Positive Resectable Stage 3-4 Oral Cavity Squamous Cell Carcinoma (OCSCC).

Squamous Cell Carcinoma | Oral Cavity Squamous Cell Carcinoma

United States
Samsung Medical Center

Recruiting

Proton Beam Radiotherapy Followed by Tecentriq and Avastin for Primary Liver Cancer With Vp2-4 Portal Vein Invasion

Hepatocellular Carcinoma | Portal Vein Thrombosis

Korea, Republic of
Ronald Buckanovich
Genentech, Inc.

Recruiting

Vismodegib Combined With Atezolizumab in Platinum Resistant Ovarian, Fallopian Tube, and Primary Peritoneal Cancer

PARP Inhibitor | Platinum-Resistant Fallopian Tube Carcinoma | Platinum-Resistant Primary Peritoneal Carcinoma | Hedgehog Inhibitor

United States
Seoul National University Bundang Hospital
Roche Pharma AG; Korean Cancer Study Group

Recruiting

KPMNG Study of MOlecular Profiling Guided Therapy Based on Genomic Alterations in Advanced Solid Tumors II (KOSMOSII)

Solid Tumor | Metastatic Cancer | Advanced Solid Tumor

Korea, Republic of
Georgetown University
Genentech, Inc.; Natera, Inc.

Recruiting

Evaluating Novel Therapies in ctDNA Positive GI Cancers (MRD-GI)

Hepatocellular Carcinoma | Pancreatic Adenocarcinoma | Gastric Adenocarcinoma | Rectal Adenocarcinoma | Colon Adenocarcinoma | Gallbladder Adenocarcinoma | Adenocarcinoma of Biliary Tract

United States
St. Jude Children's Research Hospital

Recruiting

Safety and Efficacy of Cyclophosphamide, Sorafenib, Bevacizumab, and Atezolizumab in Pediatric Solid Tumor Patients

Hepatocellular Carcinoma | Pediatric Cancer | Malignant Solid Tumor | Fibrolamellar Carcinoma | Pediatric Solid Tumor | Refractory Solid Tumor

United States
Sanofi

Recruiting

Dose Escalation and Expansion Study of SAR444200-based Regimen in Adult Participants With Advanced Solid Tumors

Neoplasm

United States, Canada, China, Korea, Republic of, Singapore
Tvardi Therapeutics, Incorporated

Recruiting

A Study of TTI-101 as Monotherapy and in Combination in Participants With Locally Advanced or Metastatic, and Unresectable Hepatocellular Carcinoma

Hepatocellular Carcinoma

United States
Exelixis

Recruiting

Study of XL092 + Atezolizumab vs Regorafenib in Subjects With Metastatic Colorectal Cancer (STELLAR-303)

Colorectal Cancer

United States, Poland, Australia, Belgium, France, Hong Kong, Korea, Republic of, Spain, Hungary, Singapore, New Zealand, Germany, Thailand, Taiwan, Portugal, United Kingdom
National Cancer Institute (NCI)

Recruiting

Testing Cabozantinib With or Without Atezolizumab in Patients With Advanced Papillary Kidney Cancer, PAPMET2 Trial

Stage IV Renal Cell Cancer AJCC v8 | Metastatic Papillary Renal Cell Carcinoma

United States
Fudan University
Roche Pharma AG

Recruiting

Efficacy and Safety of T+A+RAD in HCC

Hepatocellular Carcinoma

China

Search clinical trials for: TECENTRIQ

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Chile

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations